FOLFIRI方案二线治疗23例晚期胃癌临床观察

目的：评价FOLFIRI方案二线治疗晚期胃癌的疗效及不良反应。方法23例晚期胃癌患者采用伊立替康150 mg/m^2,静脉滴注90 min, d1；甲酰四氢叶酸（CF）200 mg/m^2,静脉滴注2 h, d1-2；5-FU 2400 mg/m^2静脉滴注46 h,每2周重复,3周期后评定疗效。结果完全缓解（CR）0例,部分缓解（PR）8例,稳定（SD）4例,进展（PD）11例,总有效率为34.7%,疾病控制率52.2%。中位PFS为3.8个月,中位OS为14.1个月,1年生存率39.1%,常见的不良反应为白细胞减少、腹泻和恶心呕吐。结论 FOLFIRI方案二线治疗晚期胃癌具有较高的疗效,不良反应可耐受且可控制。

Clinical observation of FOLFIRI regimen as second-line treatment in 23 cases of advanced gastric cancer

Objective To evaluate the effect and adverse reactions of FOLFIRI scheme second-line in the treatment of advanced gastric cancer. Methods 23 cases of patients with advanced gastric cancer using the Irinotecan for 150 mg/m^2, intravenous drip, 90 min, d1;Leucovorin （CF） 200 mg/m^2, intravenous drip 2 h, d1-2; 5-FU （2400 mg/m^2 intravenous drip 46 h, repeat every 2 weeks; After 3 cycles effect evaluation. Results Complete response （CR） 0 cases, partial response （PR） 8 cases, stable disease （SD） 4 cases, progression disease （PD） in 11 cases, the objective response rate of was 34.7%, the disease control rate was 52.2%. The median progression free survival was 3.8 months, the median overall survival time was 14.1 months and 1 year survival was 39.1%. The most common adverse reactions was leukopenia, diarrhea, nausea and vomiting. Conclusion FOLFIRI second-line in treatment of advanced gastric cancer has a high curative effect, adverse reactions can tolerance and can be controlled.